{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:43:11Z","timestamp":1789076591144,"version":"build-2803163510"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00969","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T10:07:16Z","timestamp":1593684436000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions"],"prefix":"10.3389","volume":"11","author":[{"given":"Chih-Jung","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuen-Iu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.humimm.2014.09.022","article-title":"HLA-B * 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population","volume":"75","author":"Aggarwal","year":"2014","journal-title":"Hum. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-010611-134701","article-title":"Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex","volume":"52","author":"Bharadwaj","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1086\/342571","article-title":"Stevens-Johnson syndrome associated with abacavir therapy","volume":"35","author":"Bossi","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.coi.2012.07.010","article-title":"Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis","volume":"24","author":"Camous","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int. J. Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenom. J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N\u00a0Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1212\/WNL.0000000000001034","article-title":"Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions","volume":"83","author":"Chen","year":"2014","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","article-title":"Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.jid.2018.02.004","article-title":"The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions","volume":"138","author":"Chen","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"565320","DOI":"10.1155\/2014\/565320","article-title":"HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review","volume":"2014","author":"Cheng","year":"2014","journal-title":"J. Immunol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/archdischild-2013-304767","article-title":"Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore","volume":"99","author":"Chong","year":"2014","journal-title":"Arch. Dis. Child"},{"key":"B16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jdermsci.2012.04.002","article-title":"Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis","volume":"66","author":"Chung","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions","volume":"135","author":"Chung","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J. Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and Nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1468-1331.2008.02185.x","article-title":"AAN-EFNS guidelines on trigeminal neuralgia management","volume":"15","author":"Cruccu","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jhep.2010.05.033","article-title":"Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury","volume":"53","author":"Donaldson","year":"2010","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenom. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3949\/ccjm.82a.14111","article-title":"Penicillin allergy: A practical guide for clinicians","volume":"82","author":"Gonzalez-Estrada","year":"2015","journal-title":"Cleve Clin. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S1734-1140(13)71483-X","article-title":"Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in Han individuals of northeastern China","volume":"65","author":"He","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/cpt.1706","article-title":"HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project","volume":"107","author":"Hikino","year":"2019","journal-title":"Clin. Pharmacol. Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00281-015-0540-2","article-title":"Adverse cutaneous drug eruptions: current understanding","volume":"38","author":"Hoetzenecker","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00008571-200406000-00002","article-title":"Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity","volume":"14","author":"Hughes","year":"2004","journal-title":"Pharmacogenetics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: Part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2340\/00015555-0528","article-title":"HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions","volume":"88","author":"Kano","year":"2008","journal-title":"Acta Derm. Venereol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions","volume":"44","author":"Ke","year":"2017","journal-title":"J. Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0000000000000359","article-title":"Utility of human leukocyte antigen-B*58: 01 genotyping and patient outcomes","volume":"29","author":"Ke","year":"2019","journal-title":"Pharmacogenet. Genomics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"B52","first-page":"16","article-title":"Association between HLA-B*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study","author":"Kwan","year":"2014","journal-title":"Hong Kong Med. J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/ACI.0b013e3283630cc2","article-title":"Toxic epidermal necrolysis: the year in review","volume":"13","author":"Lee","year":"2013","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000366253","article-title":"Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity","volume":"17","author":"Lee","year":"2014","journal-title":"Public Health Genomics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jaci.2014.09.041","article-title":"Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction","volume":"135","author":"Lin","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"B59","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/s0140-6736(02)07873-x","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1212\/WNL.0000000000004853","article-title":"Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients","volume":"90","author":"McCormack","year":"2018","journal-title":"Neurology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/all.13821","article-title":"HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS\/TEN in Europeans","volume":"74","author":"Mockenhaupt","year":"2019","journal-title":"Allergy"},{"key":"B69","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population","volume":"75","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","article-title":"HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese","volume":"5","author":"Nguyen","year":"2015","journal-title":"Asia Pac. Allergy"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/cpt.1493","article-title":"Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/cpt.1375","article-title":"Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","article-title":"Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity","volume":"26","author":"Norcross","year":"2012","journal-title":"AIDS"},{"key":"B75","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/eji.1830270602","article-title":"Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy","volume":"27","author":"Padovan","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1111\/j.1365-2230.2009.03508.x","article-title":"Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus","volume":"34","author":"Pahk","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41467-019-11396-2","article-title":"Identification of drug-specific public TCR driving severe cutaneous adverse reactions","volume":"10","author":"Pan","year":"2019","journal-title":"Nat. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/rheumatology\/kex253","article-title":"Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout","volume":"56","author":"Plumpton","year":"2017","journal-title":"Rheumatol. (Oxford)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5935\/0305-7518.20010009","article-title":"Increase in the incidence of dapsone hypersensitivity syndrome\u2013an appraisal","volume":"72","author":"Rao","year":"2001","journal-title":"Lepr. Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch. Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/archderm.1991.01680080069004","article-title":"Acute generalized exanthematous pustulosis. Analysis of 63 cases","volume":"127","author":"Roujeau","year":"1991","journal-title":"Arch. Dermatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1742-7843.2011.00681.x","article-title":"Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population","volume":"109","author":"Shi","year":"2011","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.12932\/AP-271118-0449","article-title":"Association of HLA genotypes with Beta-lactam antibiotic hypersensitivity in children","author":"Singvijarn","year":"2019","journal-title":"Asian Pac. J. Allergy Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e0136141","DOI":"10.1371\/journal.pone.0136141","article-title":"The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects","volume":"10","author":"Tanno","year":"2015","journal-title":"PloS One"},{"key":"B93","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"B94","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","article-title":"Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population","volume":"26","author":"Tassaneeyakul","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"key":"B95","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/FPC.0000000000000306","article-title":"Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population","volume":"27","author":"Tempark","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"B96","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11096-013-9777-9","article-title":"Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand","volume":"35","author":"Tiamkao","year":"2013","journal-title":"Int. J. Clin. Pharm."},{"key":"B97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenom. J."},{"key":"B98","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaci.2013.04.036","article-title":"A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders","volume":"132","author":"Wang","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jdermsci.2017.08.007","article-title":"A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome","volume":"88","author":"Watanabe","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clindermatol.2004.06.012","article-title":"Life-threatening acute adverse cutaneous drug reactions","volume":"23","author":"Wolf","year":"2005","journal-title":"Clin. Dermatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/00029330-200603020-00005","article-title":"HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins","volume":"119","author":"Yang","year":"2006","journal-title":"Chin. Med. J. (Engl.)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/ijms18071464","article-title":"Structural Elements Recognized by Abacavir-Induced T Cells","volume":"18","author":"Yerly","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12016-014-8418-y","article-title":"Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review","volume":"48","author":"Yip","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01","volume":"192","author":"Yun","year":"2014","journal-title":"J. Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5415\/apallergy.2016.6.2.77","article-title":"T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance","volume":"6","author":"Yun","year":"2016","journal-title":"Asia Pac. Allergy"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T10:07:18Z","timestamp":1593684438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":108,"alternative-id":["10.3389\/fphar.2020.00969"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00969","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"article-number":"969"}}